Sonnet BioTherapeutics, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Narrative)

Commitments and Contingencies (Details Narrative) € in Millions	1 Months Ended			12 Months Ended
	Aug. 31, 2024	Apr. 30, 2022 USD ($)	Mar. 31, 2022 USD ($)	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 EUR (€)	Apr. 30, 2023 USD ($)	Mar. 31, 2023 USD ($)	Jan. 31, 2019 USD ($)	Jul. 31, 2012 USD ($)
Loss Contingencies [Line Items]
Payment to acquire in process research and development				$ 12,000	$ 443,250
Discovery Collaboration Agreements [Member] \| XOMA [Member]
Loss Contingencies [Line Items]
Milestone payments										$ 3,800,000
Discovery Collaboration Agreements [Member] \| XOMA [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees		$ 500,000		$ 0	0
Cellca Agreement [Member]
Loss Contingencies [Line Items]
Description of milestone payments				The Company is obligated to make milestone payments to Cellca totaling up to $0.7 million upon the achievement of certain development and approval milestones if the Buy-Out Option is not exercised.
Cellca Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Milestone payments									$ 700,000
The Cellca Agreement [Member]
Loss Contingencies [Line Items]
Milestone payments				$ 600,000
The Cellca Agreement [Member] \| Maximum [Member]
Loss Contingencies [Line Items]
Payment for annual license fee obligation				600,000
The Cellca Agreement [Member] \| Minimum [Member]
Loss Contingencies [Line Items]
Payment for annual license fee obligation				100,000
The Cellca Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees				0	0
Commercial product license fee payment obligation		$ 100,000
The Brink Agreement [Member]
Loss Contingencies [Line Items]
Commercial product license fee payment obligation				100,000
Payment of annual license fee							$ 12,000
The Brink Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees				12,000	12,000
Development license fee payments				100,000
InvivoGen Agreement [Member]
Loss Contingencies [Line Items]
License fees				0	0
Payment for annual license fee obligation				100,000		€ 0.1
ProteoNic Agreement [Member]
Loss Contingencies [Line Items]
License fees				0	0
ProteoNic Agreement [Member] \| In Process Research and Development [Member]
Loss Contingencies [Line Items]
License fees			$ 24,600
SOC Agreement [Member]
Loss Contingencies [Line Items]
Agreements description	the Company establishes a partnership with a third party prior to the initiation of the initial efficacy combination trial under this collaboration, the Company will incur to the SOC a one-time fee equal to the greater of 5% or $1.5 million from the first upfront payment received from such third-party partnership.
Navigo Agreement [Member] \| Navigo Proteins GmbH [Member] \| Technology Service [Member]
Loss Contingencies [Line Items]
Milestone payments								$ 1,000,000.0
Payment to acquire in process research and development				100,000
Navigo Agreement [Member] \| Navigo Proteins GmbH [Member] \| Technology Service [Member] \| Research and Development Expense [Member]
Loss Contingencies [Line Items]
Milestone payments				0
License fees				$ 0	$ 300,000